Swedish animal-health group providing veterinary diagnostics, specialty pharma and pet-care products, built through acquisitions.
Swedish animal-health group providing veterinary diagnostics, specialty pharma and pet-care products, built through acquisitions.
In one line: A smaller, roll-up version of IDEXX Laboratories/Zoetis.
Moat: narrow (installed base, customer qualification). Niche diagnostics/specialty products with vet-clinic relationships, in a market led by larger scaled players.
Headquarters: Stockholm, Sweden · Founded: 2021 · Employees: 1,300
Size Vimian (VIMIAN.ST) is a Sweden Health Care company (Biotechnology) with a market value of $2.26B, the 72nd largest of 220 Sweden companies the cockpit tracks. Shares closed at SEK 43.50 on 18 Nov 2026.
Performance Over six months the shares gained 50.8%, against -10.8% for the median peer and +2.8% for the Sweden market (cap-weighted) — 5th highest of 20 in its peer set.
Growth Revenue grew 8.0% over the last twelve months (peer median +5.5%); the operating margin is 19.2% (peer median -19.9%).
Valuation It trades at 38.4× forward earnings against a peer median of 18.1× (3rd most expensive of 6).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +44%, so the hurdle is -31 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points below its cost of capital (7.3% WACC).
Next results Next results expected around 11 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | SEK 5.09B | SEK 4.70B | SEK 4.29B | SEK 3.81B | SEK 2.99B |
| Revenue growth | — | +10% | +13% | +27% | — |
| Gross profit | SEK 977M | SEK 799M | SEK 690M | SEK 596M | SEK 570M |
| EBITDA | SEK 1.44B | SEK 1.22B | SEK 1.08B | SEK 963M | SEK 860M |
| Net income | SEK 428M | SEK 346M | SEK 212M | SEK 113M | -SEK 71.7M |
| Free cash flow | SEK 1.03B | SEK 1.07B | SEK 592M | -SEK 419M | SEK 207M |
| Capital expenditure | SEK 234M | SEK 167M | SEK 162M | SEK 171M | SEK 110M |
| Total debt | SEK 3.18B | SEK 2.58B | SEK 2.67B | SEK 3.49B | SEK 2.46B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Vimian VIMIAN.ST | $2.26B | +51% | +8% | 19% | 38.4× | 13.4% |
| Idexx Laboratories IDXX | $55.0B | +26% | +12% | 32% | 42.9× | 29.0% |
| Zoetis ZTS | $34.8B | +7% | +1% | 37% | 13.8× | -2.9% |
| Elanco Animal Health ELAN | $13.3B | +28% | +12% | 8% | 21.5× | 32.9% |
| Virbac VIRP.PA | $3.20B | -4% | +4% | 15% | 16.6× | 5.8% |
| Vetoquinol VETO.PA | $1.10B | +19% | -1% | 15% | 15.5× | -3.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | VIMIAN.ST | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +14.3% | -4.9% | 4th highest of 21 |
| 6-month return | +50.8% | -10.8% | 5th highest of 20 |
| Distance from 52-week high | -0.1% | -35.4% | highest of 21 |
| Revenue growth (TTM) | +8.0% | +5.5% | 9th highest of 17 |
| Operating margin | 19.2% | -19.9% | 5th highest of 15 |
| Forward P/E | 38.4× | 18.1× | 3rd most expensive of 6 |
| Growth the price implies (Req g, 7 yrs) | 13.4% | 3.5% | 2nd most demanding of 4 |
| Growth delivered (Del g) | +44.5% | +36.0% | highest of 4 |
| Hurdle (Req g minus delivered) | -31.1 pp | -36.6 pp | 2nd most demanding of 4 |
| ROIC minus cost of capital | -0.4 pp | -11.0 pp | 5th highest of 12 |
| EV / EBITDA | 17.8× | n/a | — |
| Net debt / EBITDA | 1.8× | -2.6× | 2nd most indebted of 4 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Vimian VIMIAN.ST | Sweden | $2.26B | +51% | +8% | 19% | 38.4× | 13.4% | +44.5% |
| SKBS 302440.KS | South Korea | $2.25B | -12% | +11% | -23% | n/a | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.26B | +31% | +223% | 64% | n/a | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.27B | -34% | -58% | -475% | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.21B | +7% | n/a | n/a | n/a | n/a | n/a |
| Hebei Changshan Biochemical Pharmaceutical 300255.SZ | China | $2.33B | -59% | 0% | -25% | n/a | n/a | n/a |
| Beam Therapeutics BEAM | United States | $2.17B | -22% | +163% | -268% | n/a | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.16B | -11% | -94% | -211,685% | n/a | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.16B | -30% | -50% | 46% | 7.2× | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.14B | +27% | -100% | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.13B | -15% | 0% | -14% | 126.7× | n/a | n/a |
| Alamar Biosciences ALMR | United States | $2.12B | +51% | +195% | -42% | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.08B | n/a | n/a | n/a | n/a | n/a | n/a |
| Walvax Biotechnology 300142.SZ | China | $2.48B | -26% | -23% | 5% | 348.7× | 29.5% | -3.8% |
| Aurinia Pharmaceuticals AUPH | United States | $2.03B | -5% | +21% | 45% | 18.1× | 3.5% | +41.4% |
| Xiamen Amoytop Biotech 688278.SS | China | $2.56B | -27% | +18% | 27% | 15.0× | -0.6% | +36.0% |
| Immunome IMNM | United States | $1.98B | -22% | -100% | n/a | n/a | n/a | n/a |
| Xencor XNCR | United States | $2.58B | +204% | +34% | -73% | n/a | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $1.93B | -3% | n/a | n/a | n/a | n/a | n/a |
| Maravai Lifesciences MRVI | United States | $1.92B | +101% | +11% | -17% | n/a | n/a | n/a |
| MBX Biosciences MBX | United States | $2.65B | +70% | n/a | n/a | n/a | n/a | n/a |